Appeals court revives suit against Sanofi's Genzyme over access to Fabry disease drug
An appeals court ruling from late last week will revive a lawsuit over a Sanofi subsidiary’s contamination issues and a subsequent shortage of a key rare disease drug.
At issue in the case is a series of alleged blunders related to the supply of Genzyme’s drug for treating Fabry disease, a rare neurological disorder that can lead to kidney failure, heart failure or stroke.
The revived lawsuit, filed in 2020 in a Massachusetts federal court, seeks monetary damages for more than two dozen Fabry patients who allege they were injured by the company’s handling of the contamination and subsequent shortage of the drug, marketed as Fabrazyme, that occurred between 2009 and 2012. Sanofi acquired Genzyme for about $20 billion in 2011.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
